Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$135.90 USD
-1.03 (-0.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.97 +0.07 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASND 135.90 -1.03(-0.75%)
Will ASND be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Other News for ASND
Looking Into Ascendis Pharma's Recent Short Interest
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Ascendis Pharma Gains UK Authorization for YORVIPATH
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Ascendis Pharma announces MRHA approval of YORVIPATH in Great Britain